Novartis (NVS) Stock Forecast & Price Target

Q: What analysts cover Novartis?

Novartis has been rated by research analysts at Citigroup , Deutsche Bank Aktiengesellschaft , HSBC , Royal Bank Of Canada , and Weiss Ratings in the past 90 days.

$137.22 -0.26 (-0.19%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$137.01 -0.21 (-0.15%)

As of 09/11/2026 08:00 PM Eastern

Compare

Novartis - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 16 Analyst Ratings

Sell
0

Hold
10

Buy
6

Based on 16 Wall Street analysts who have issued ratings for Novartis in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 analysts, 10 have given a hold rating, and 6 have given a buy rating for NVS.

Consensus Price Target

$153.00
11.50% Upside

According to the 16 analysts' twelve-month price targets for Novartis, the average price target is $153.00. The highest price target for NVS is $180.00, while the lowest price target for NVS is $126.00. The average price target represents a forecasted upside of 11.50% from the current price of $137.22.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for NVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novartis and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVS Analyst Ratings Over Time

Type	Current Forecast 9/13/25 to 9/13/26	1 Month Ago 8/14/25 to 8/14/26	3 Months Ago 6/15/25 to 6/15/26	1 Year Ago 9/13/24 to 9/13/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	6 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	1 Buy rating(s)
Hold	10 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$153.00	$141.20	$141.20	$120.33
Forecasted Upside	11.50% Upside	-6.50% Downside	-6.89% Downside	-3.05% Downside
Consensus Rating	Hold	Hold	Hold	Hold

NVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novartis Stock vs. The Competition

Type	Novartis	Healthcare Companies	Broader Market
Consensus Rating Score	2.38	2.30	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	11.50% Upside	891.32% Upside	16.41% Upside
News Sentiment Rating	Neutral News See Recent NVS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/10/2026	HSBC 2 of 5 stars		Set Target		$136.00	-1.10%
9/8/2026	Deutsche Bank Aktiengesellschaft 2 of 5 stars		Downgrade	Buy ➝ Hold
9/8/2026	Royal Bank Of Canada 3 of 5 stars		Initiated Coverage	Sector Perform
7/24/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy (B)
7/22/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
3/26/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mark Purcell Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$143.00 ➝ $170.00	+13.10%
3/19/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold
3/11/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy	$180.00	+11.36%
2/17/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
2/9/2026	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
Get the Latest News and Ratings for NVS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.
1/6/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emmanuel Papada Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight
12/8/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Vosser Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
11/25/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Buy
10/29/2025	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Wan Nurhayati Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Hold	$126.00	+2.09%
10/27/2025	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Neutral
10/27/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Leuchten Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
9/12/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Quigley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell	$119.00 ➝ $118.00	-7.54%
4/15/2025	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Verdult Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
2/13/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Weston Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
11/19/2024	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
10/30/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Market Perform	$118.00 ➝ $120.00	+8.53%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:36 PM ET.

Should I Buy Novartis Stock? NVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 11, 2026. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

Novartis
Bull Case

Here are some ways that investors could benefit from investing in Novartis AG:

Novartis AG currently trades at $137.22, which is significantly below its 52-week high of $170.46, potentially offering a valuation entry point for investors who believe the recent market overreaction to clinical setbacks is excessive.
The company maintains a strong financial profile with a return on equity of 38.56% and a net margin of 23.29% in its most recent reported quarter, indicating efficient capital usage and robust profitability despite recent operational challenges.
Novartis AG offers a dividend yield of 2.24%, providing a steady income stream for investors, which is supported by the company's reaffirmed sales guidance through 2030 that suggests near-term performance remains stable.
With a beta of 0.45, the stock exhibits lower volatility compared to the broader market, making it a potentially defensive holding for investors seeking stability in their portfolio during periods of market uncertainty.
The company has a diversified portfolio of approved medicines addressing major disease areas such as cardiovascular, renal, and metabolic conditions, which helps mitigate risk by not relying on a single product for revenue generation.

Novartis
Bear Case

Investors should be bearish about investing in Novartis AG for these reasons:

Novartis AG recently suffered a significant market-value wipeout of approximately $30 billion following the failure of its Phase 3 HARBOR study of del-desiran and the Phase 3 HORIZON study of pelacarsen, which failed to meet their primary endpoints.
A major shareholder has called for a board shake-up to improve corporate governance following the record weekly decline in stock price, which could lead to management instability and increased pressure on the company's leadership.
Deutsche Bank downgraded Novartis AG from a "buy" to a "hold" rating, signaling weaker confidence in the company's near- to medium-term growth prospects after the twin trial failures extended the selloff.
A shareholder-related law firm has announced an investigation into potential securities-law violations connected with the disclosures and resulting decline, adding legal and reputational risk to the company.
The stock is currently trading below its 50-day simple moving average of $154.63 and 200-day simple moving average of $153.11, indicating a bearish technical trend that may persist as investors reassess the company's pipeline.

NVS Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Novartis is $153.00, with a high forecast of $180.00 and a low forecast of $126.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 10 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.

According to analysts, Novartis's stock has a predicted upside of 11.50% based on their 12-month stock forecasts.

Over the previous 90 days, Novartis's stock had 1 upgrade and 1 downgrade by analysts.

Novartis has been rated by research analysts at Citigroup, Deutsche Bank Aktiengesellschaft, HSBC, Royal Bank Of Canada, and Weiss Ratings in the past 90 days.

Analysts like Novartis more than other "healthcare" companies. The consensus rating score for Novartis is 2.38 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how NVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Novartis Recommendations

MarketBeat monitors more than a dozen sources for Novartis analyst ratings, with the most recent rating issued on 9/10/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novartis (NVS) Stock Forecast & Price Target